|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI
|
|
3
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramos A, Sadeghi S and Tabatabaeian H:
Battling chemoresistance in cancer: Root causes and strategies to
uproot them. Int J Mol Sci. 22:94512021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hrycyna CA: Molecular genetic analysis and
biochemical characterization of mammalian P-glycoproteins involved
in multidrug resistance. Semin Cell Dev Biol. 12:247–256. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmed N, Escalona R, Leung D, Chan E and
Kannourakis G: Tumour microenvironment and metabolic plasticity in
cancer and cancer stem cells: Perspectives on metabolic and immune
regulatory signatures in chemoresistant ovarian cancer stem cells.
Semin Cancer Biol. 53:265–281. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Zhang L, Liu J, Zhang J and Xu G:
Highly expressed STAT1 contributes to the suppression of stemness
properties in human paclitaxel-resistant ovarian cancer cells.
Aging (Albany NY). 12:11042–11060. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Foster R, Buckanovich RJ and Rueda BR:
Ovarian cancer stem cells: Working towards the root of stemness.
Cancer Lett. 338:147–157. 2013. View Article : Google Scholar
|
|
9
|
Garson K and Vanderhyden BC: Epithelial
ovarian cancer stem cells: Underlying complexity of a simple
paradigm. Reproduction. 149:R59–R70. 2015. View Article : Google Scholar
|
|
10
|
Gerardo-Ramirez M, Keggenhoff FL, Giam V,
Becker D, Groth M, Hartmann N, Straub BK, Morrison H, Galle PR,
Marquardt JU, et al: CD44 contributes to the regulation of MDR1
protein and doxorubicin chemoresistance in osteosarcoma. Int J Mol
Sci. 23:86162022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zaccara S, Ries RJ and Jaffrey SR:
Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell
Biol. 20:608–624. 2019. View Article : Google Scholar
|
|
12
|
Lan Q, Liu PY, Bell JL, Wang JY,
Hüttelmaier S, Zhang XD, Zhang L and Liu T: The emerging roles of
RNA m6A methylation and demethylation as critical
regulators of tumorigenesis, drug sensitivity, and resistance.
Cancer Res. 81:3431–3440. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hiriart E, Gruffat H, Buisson M, Mikaelian
I, Keppler S, Meresse P, Mercher T, Bernard OA, Sergeant A and
Manet E: Interaction of the Epstein-Barr virus mRNA export factor
EB2 with human Spen proteins SHARP, OTT1, and a novel member of the
family, OTT3, links Spen proteins with splicing regulation and mRNA
export. J Biol Chem. 280:36935–36945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Y, Hsu PJ, Chen YS and Yang YG:
Dynamic transcriptomic m6A decoration: writers, erasers,
readers and functions in RNA metabolism. Cell Res. 28:616–624.
2018. View Article : Google Scholar :
|
|
15
|
Yang F, Liu Y, Xiao J, Li B, Chen Y, Hu A,
Zeng J, Liu Z and Liu H: Circ-CTNNB1 drives aerobic glycolysis and
osteosarcoma progression via m6A modification through interacting
with RBM15. Cell Prolif. 56:e133442023. View Article : Google Scholar
|
|
16
|
Wang X, Tian L, Li Y, Wang J, Yan B, Yang
L, Li Q, Zhao R, Liu M, Wang P and Sun Y: RBM15 facilitates
laryngeal squamous cell carcinoma progression by regulating TMBIM6
stability through IGF2BP3 dependent. J Exp Clin Cancer Res.
40:802021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Z, Ju Q, Ji J, Li Y and Zhao Y:
N6-methyladenosine methylation regulator RBM15 is a potential
prognostic biomarker and promotes cell proliferation in pancreatic
adenocarcinoma. Front Mol Biosci. 9:8428332022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Zhao X and Lu Z: m6A
RNA methylation regulators act as potential prognostic biomarkers
in lung adenocarcinoma. Front Genet. 12:6222332021. View Article : Google Scholar
|
|
19
|
Jang KH, Heras CR and Lee G:
m6A in the signal transduction network. Mol Cells.
45:435–443. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwok AL, Wong OG, Wong ES, Tsun OK, Chan
KK and Cheung AN: Caution over use of ES2 as a model of ovarian
clear cell carcinoma. J Clin Pathol. 67:921–922. 2014. View Article : Google Scholar
|
|
21
|
Zhang J, Guan W, Xu X, Wang F, Li X and Xu
G: A novel homeostatic loop of sorcin drives paclitaxel-resistance
and malignant progression via Smad4/ZEB1/miR-142-5p in human
ovarian cancer. Oncogene. 40:4906–4918. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Zhang L, Zhou D, Guan W, Ren W, Sun W, Shi
J, Lin Q, Zhang J, Qiao T, Ye Y, et al: Pyridoxine 5'-phosphate
oxidase is a novel therapeutic target and regulated by the TGF-β
signalling pathway in epithelial ovarian cancer. Cell Death Dis.
8:32142017. View Article : Google Scholar
|
|
24
|
Edgar R, Domrachev M and Lash AE: Gene
expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar :
|
|
25
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45(W1):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geeleher P, Cox N and Huang RS:
pRRophetic: An R package for prediction of clinical
chemotherapeutic response from tumor gene expression levels. PLoS
One. 9:e1074682014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou Y, Zeng P, Li YH, Zhang Z and Cui Q:
SRAMP: Prediction of mammalian N6-methyladenosine (m6A) sites based
on sequence-derived features. Nucleic Acids Res. 44:e912016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Castro-Mondragon JA, Riudavets-Puig R,
Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, Lucas J,
Boddie P, Khan A, Manosalva Pérez N, et al: JASPAR 2022: The 9th
release of the open-access database of transcription factor binding
profiles. Nucleic Acids Res. 50(D1): D165–D173. 2022. View Article : Google Scholar :
|
|
33
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong H, Zhang H, Mao X, Liu S, Xu W and
Zhang Y: RBM15 promates the proliferation, migration and invasion
of pancreatic cancer cell lines. Cancers (Basel). 15:10842023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng X, Chen K, Li L, Tian J, Ruan W, Hu
Z, Peng D and Chen Z: Epigenetic activation of RBM15 promotes clear
cell renal cell carcinoma growth, metastasis and macrophage
infiltration by regulating the m6A modification of CXCL11. Free
Radic Biol Med. 184:135–147. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ayob AZ and Ramasamy TS: Cancer stem cells
as key drivers of tumour progression. J Biomed Sci. 25:202018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abdullah LN and Chow EKH: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elzarkaa AA, Sabaa BE, Abdelkhalik D,
Mansour H, Melis M, Shaalan W, Farouk M, Malik E and Soliman AA:
Clinical relevance of CD44 surface expression in advanced stage
serous epithelial ovarian cancer: A prospective study. J Cancer Res
Clin Oncol. 142:949–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao Y, Foster R, Yang X, Feng Y, Shen JK,
Mankin HJ, Hornicek FJ, Amiji MM and Duan Z: Up-regulation of CD44
in the development of metastasis, recurrence and drug resistance of
ovarian cancer. Oncotarget. 6:9313–9326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cai X, Chen Y, Man D, Yang B, Feng X,
Zhang D, Chen J and Wu J: RBM15 promotes hepatocellular carcinoma
progression by regulating N6-methyladenosine modification of YES1
mRNA in an IGF2BP1-dependent manner. Cell Death Discov. 7:3152021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fang J, Wu X, He J, Zhang H, Chen X, Zhang
H, Novakovic B, Qi H and Yu X: RBM15 suppresses hepatic insulin
sensitivity of offspring of gestational diabetes mellitus mice via
m6A-mediated regulation of CLDN4. Mol Med. 29:232023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang W, Yang S, Cheng YS, Sima N, Sun W,
Shen M, Braisted JC, Lu W and Zheng W: Terfenadine resensitizes
doxorubicin activity in drug-resistant ovarian cancer cells via an
inhibition of CaMKII/CREB1 mediated ABCB1 expression. Front Oncol.
12:10684432022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Su S, Sun X, Zhang Q, Zhang Z and Chen J:
CCL20 promotes ovarian cancer chemotherapy resistance by regulating
ABCB1 expression. Cell Struct Funct. 44:21–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vaidyanathan A, Sawers L, Gannon AL,
Chakravarty P, Scott AL, Bray SE, Ferguson MJ and Smith G: ABCB1
(MDR1) induction defines a common resistance mechanism in
paclitaxeland olaparib-resistant ovarian cancer cells. Br J Cancer.
115:431–441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang T, Kong S, Tao M and Ju S: The
potential role of RNA N6-methyladenosine in Cancer progression. Mol
Cancer. 19:882020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ikushima H and Miyazono K: TGFbeta
signalling: A complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Katsuno Y, Meyer DS, Zhang Z, Shokat KM,
Akhurst RJ, Miyazono K and Derynck R: Chronic TGF-β exposure drives
stabilized EMT, tumor stemness, and cancer drug resistance with
vulnerability to bitopic mTOR inhibition. Sci Signal.
12:eaau85442019. View Article : Google Scholar
|
